YU163075A
(en)
|
1975-07-21 |
1982-05-31 |
Science Union & Cie |
Process for preparing new phenoxy derivatives
|
JP2969359B2
(ja)
|
1989-01-13 |
1999-11-02 |
武田薬品工業株式会社 |
環状アミン化合物
|
IE912760A1
(en)
|
1990-08-06 |
1992-02-12 |
Smith Kline French Lab |
Compounds
|
DK0641320T3
(da)
|
1991-04-17 |
2001-08-20 |
Upjohn Co |
Substituerede (S)-3-phenylpiperidinderivater, deres fremstilling og deres anvendelse som dopaminautoreceptorantagonister
|
US5236934A
(en)
*
|
1992-08-26 |
1993-08-17 |
E. I. Du Pont De Nemours And Company |
1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
|
JPH11501281A
(ja)
|
1993-06-18 |
1999-02-02 |
ユニバーシティ オブ シンシナティ |
神経ペプチドyアンタゴニスト及びアゴニスト
|
US5863903A
(en)
|
1994-03-09 |
1999-01-26 |
Novo Nordisk A/S |
Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
|
CA2187257A1
(en)
|
1995-10-12 |
1997-04-13 |
Enrique Luis Michelotti |
Aryl-substituted cycloalkanes and cycloalkenes and herbicidal use thereof
|
US5977134A
(en)
*
|
1996-12-05 |
1999-11-02 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
BR9810991A
(pt)
*
|
1997-07-11 |
2000-08-08 |
Smithkline Beecham Plc |
Novos compostos
|
EP1295873A4
(en)
|
2000-06-14 |
2004-05-19 |
|
METHODS OF PRODUCING RACEMIC PIPERIDINE DERIVATIVE AND PRODUCING OPTICALLY ACTIVE PIPERIDINE DERIVATIVE
|
US7148197B2
(en)
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
AR031152A1
(es)
|
2000-10-31 |
2003-09-10 |
Upjohn Co |
Tratamientos nuevos para el sindrome de piernas inquietas
|
WO2003072558A2
(en)
|
2002-02-22 |
2003-09-04 |
Pharmacia & Upjohn Company |
Arylsulfone derivatives
|
US20040082641A1
(en)
|
2002-10-28 |
2004-04-29 |
Rytved Klaus Asger |
Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
|
WO2004043929A1
(en)
|
2002-11-12 |
2004-05-27 |
Pfizer Products Inc. |
Quinoline derivatives
|
SE0300010D0
(sv)
|
2003-01-07 |
2003-01-07 |
Astrazeneca Ab |
Novel Compounds
|
US20040192728A1
(en)
|
2003-02-03 |
2004-09-30 |
Ellen Codd |
Quinoline-derived amide modulators of vanilloid VR1 receptor
|
US20060293298A1
(en)
|
2003-04-10 |
2006-12-28 |
Bamford Mark J |
Compounds
|
WO2005000309A2
(en)
|
2003-06-27 |
2005-01-06 |
Ionix Pharmaceuticals Limited |
Chemical compounds
|
US7268232B2
(en)
|
2004-05-17 |
2007-09-11 |
Acadia Pharmaceuticals Inc. |
Androgen receptor modulators and method of treating disease using the same
|
WO2006049597A1
(en)
|
2004-10-27 |
2006-05-11 |
Avanir Pharmaceuticals |
Amino acid-derived compounds as modulators of the reverse cholesterol transport
|
CA2613236A1
(en)
|
2005-06-30 |
2007-01-11 |
Prosidion Limited |
G-protein coupled receptor agonists
|
GB0514812D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
DE102005044817A1
(de)
*
|
2005-09-20 |
2007-03-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
|
AU2006333522A1
(en)
|
2005-12-21 |
2007-07-12 |
Decode Genetics, Ehf. |
Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation
|
US20090042857A1
(en)
|
2006-02-20 |
2009-02-12 |
Masuo Yamaoka |
Novel Pharmaceutical
|
US7834178B2
(en)
|
2006-03-01 |
2010-11-16 |
Bristol-Myers Squibb Company |
Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
|
US9187485B2
(en)
|
2007-02-02 |
2015-11-17 |
Baylor College Of Medicine |
Methods and compositions for the treatment of cancer and related hyperproliferative disorders
|
EP2170866B1
(en)
|
2007-06-25 |
2014-08-13 |
Amgen Inc. |
Phthalazine compounds, compositions and methods of use
|
US8673850B2
(en)
|
2008-05-30 |
2014-03-18 |
Institut De Recherches Cliniques De Montreal |
PCSK9 inhibitors and methods of use thereof
|
US8324385B2
(en)
|
2008-10-30 |
2012-12-04 |
Madrigal Pharmaceuticals, Inc. |
Diacylglycerol acyltransferase inhibitors
|
EP2483266B1
(en)
|
2009-10-01 |
2015-02-25 |
Cadila Healthcare Limited |
Compounds for the treatment of dyslipidemia and related diseases
|
WO2012039660A1
(en)
|
2010-09-20 |
2012-03-29 |
A. Carlsson Research Ab |
Phenylpiperidine compounds for the treatment of neurological and psychiatric disorders
|
JP5934787B2
(ja)
*
|
2011-05-10 |
2016-06-15 |
ギリアード サイエンシーズ, インコーポレイテッド |
イオンチャネルモジュレーターとしての縮合複素環式化合物
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
AU2013266087A1
(en)
|
2012-05-25 |
2014-12-04 |
Catabasis Pharmaceuticals, Inc. |
Methods of lowering proprotein convertase subtilisin/kexin type 9 (PCSK9)
|
WO2014002105A1
(en)
|
2012-06-25 |
2014-01-03 |
Cadila Healthcare Limited |
Compounds for the treatment of dyslipidemia and other diseases
|
CN103602337B
(zh)
|
2012-08-17 |
2015-04-29 |
石家庄诚志永华显示材料有限公司 |
环己烷衍生物及其制备方法与应用
|
WO2014101120A1
(en)
|
2012-12-28 |
2014-07-03 |
Merck Sharp & Dohme Corp. |
Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
|
US10287317B2
(en)
|
2013-02-15 |
2019-05-14 |
Srx Cardio, Llc |
Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels
|
JP2016508722A
(ja)
|
2013-02-15 |
2016-03-24 |
エスアールエックス カーディオ,エル エル シー |
血清低密度リポタンパク質(ldl)レベルを調節するためのpcsk9(プロタンパク質転換酵素サブチリシン/ケキシン9型)アロステリック結合リガンド
|
ES2489815B1
(es)
|
2013-02-21 |
2015-08-10 |
Centro De Investigación Príncipe Felipe |
Nuevos p-terfenilos hexakis-sustituidos con grupos bilaterales para el tratamiento de la infección por el virus de la inmunodeficiencia humana tipo 1 (VIH-1) y otras enfermedades
|
CN105473141A
(zh)
|
2013-03-15 |
2016-04-06 |
实发生物医学公司 |
治疗和/或预防心血管疾病的抗pcsk9化合物和方法
|
WO2014150983A2
(en)
|
2013-03-15 |
2014-09-25 |
Amgen Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
WO2015024016A2
(en)
|
2013-08-16 |
2015-02-19 |
Duke University |
2-piperidinyl substituted n,3-dihydroxybutanamides
|
WO2015058129A1
(en)
|
2013-10-17 |
2015-04-23 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
US10034892B2
(en)
|
2014-08-21 |
2018-07-31 |
Srx Cardio, Llc |
Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity
|
US20170267689A1
(en)
|
2014-08-25 |
2017-09-21 |
The Governors Of The University Of Alberta |
Stimuli-switchable moieties, monomers and polymers incorporating stimuli-switchable moieties, and methods of making and using same
|
WO2016107602A1
(zh)
|
2015-01-01 |
2016-07-07 |
成都贝斯凯瑞生物科技有限公司 |
一类取代氮杂环衍生物及其应用
|
WO2016107603A1
(zh)
|
2015-01-01 |
2016-07-07 |
成都贝斯凯瑞生物科技有限公司 |
取代氮杂环衍生物及其应用
|
WO2017034990A1
(en)
|
2015-08-21 |
2017-03-02 |
Portola Pharmaceuticals, Inc. |
Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity
|
EP3337788A4
(en)
|
2015-08-21 |
2019-03-27 |
Portola Pharmaceuticals, Inc. |
PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN / -KEXIN TYPE 9 P (CSK9) MODULATORS AND THEIR USE
|
WO2017034994A1
(en)
|
2015-08-21 |
2017-03-02 |
Portola Pharmaceuticals, Inc. |
Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity
|
DK3386511T3
(da)
|
2015-12-10 |
2021-07-05 |
Ptc Therapeutics Inc |
Fremgangsmåder til behandling af huntingtons sygdom
|
US20190119236A1
(en)
|
2016-02-23 |
2019-04-25 |
Portola Pharmaceuticals, Inc. |
Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
WO2018026866A1
(en)
|
2016-08-03 |
2018-02-08 |
Neuropore Therapies, Inc. |
Lipid-substituted amino 1,2-and 1,3-diol compounds as modulators of tlr2 dimerization
|
EP3609882B1
(en)
|
2017-03-17 |
2022-07-13 |
Cardio Therapeutics Pty Ltd |
Heterocyclic inhibitors of pcsk9
|
AU2020291468A1
(en)
|
2019-06-14 |
2022-01-06 |
Srx Cardio, Llc |
Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
|
US20220193058A1
(en)
|
2020-12-16 |
2022-06-23 |
Srx Cardio, Llc |
Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (pcsk9)
|